Mergers and Acquisitions

Date: 2022-04-11

Type of information: Company acquisition

Acquired company: Arranta Bio (USA-MA)

Acquiring company: Recipharm (Sweden)

Amount: undisclosed


• On Recipharm announced the acquisition of Arranta Bio, a prominent advanced therapy CDMO. Under the stewardship of Mark Bamforth and backed by Ampersand Capital Partners, the company has established a strong service portfolio as a leader in delivering microbiome therapeutic products and mRNA clinical production capabilities. The acquisition forms a cornerstone of Recipharm’s strategy to provide innovative drug developers in the Biologics market with scientifically differentiated contract development and manufacturing services for ATMPs and builds on the capabilities acquired through the recently announced GenIbet transaction and the acquisition of Vibalogics. The acquisition is expected to be completed around the end of March 2022, subject to customary regulatory filings. Centerview Partners UK LLP acted as exclusive financial adviser, and Kirkland & Ellis LLP served as counsel to Recipharm on the transaction. Morgan Stanley & Co. LLC acted as exclusive financial adviser and Goodwin Procter LLP served as counsel to Arranta Bio.


Related: manufacturing bioproduction

Is general: Yes